Curamir is developing innovative therapeutics based on its proprietary miRNA engineering platform and insights into cancer biology, aiming to address unmet needs to overcome drug resistance and toxicity associated with current oncology therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/23/19 | $10,000,000 | Series A |
Delos Capital | undisclosed |
